Korea’s Green Gross, Russia’s Pharmstandard Lead $42.5M Argos Financing; Take Local Rights
This article was originally published in PharmAsia News
Executive Summary
The personalized immunotherapy developer partnered with Korea’s Green Cross and Russia’s Pharmstandard but avoided giving away major-market rights to its late-stage program in metastatic renal cell carcinoma. If it completes its proposed $60 million Series E round, its Phase III trial will be funded to completion.